OverviewSuggest Edit

Morphic Therapeutic operates as a biotechnology company. The company develops oral integrin drugs. It is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders, and immuno-oncology.
TypePublic
Founded2015
HQWaltham, MA, US
Websitemorphictx.com
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2019)76
Revenue (FY, 2019)$3.4 M
Share Price (Jan 2021)$29.8 (-2%)
Cybersecurity ratingAMore

Morphic Therapeutic Office Locations

Morphic Therapeutic has an office in Waltham
Waltham, MA, US (HQ)
35 Gatehouse Dr
Show all (1)

Morphic Therapeutic Financials and Metrics

Morphic Therapeutic Revenue

Morphic Therapeutic's revenue was reported to be $3.36 m in FY, 2019
USD

Revenue (Q2, 2020)

7.7m

Net income (Q2, 2020)

(15.9m)

EBIT (Q2, 2020)

(16.4m)

Market capitalization (11-Jan-2021)

926.6m

Closing stock price (11-Jan-2021)

29.8

Cash (30-Jun-2020)

133.1m
Morphic Therapeutic's current market capitalization is $926.6 m.
Annual
USDFY, 2017FY, 2019

Revenue

3.4m

General and administrative expense

2.8m5.4m

R&D expense

14.1m22.6m

Operating expense total

16.9m28.0m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

5.6m5.6m7.7m

General and administrative expense

2.1m2.9m4.4m4.2m

R&D expense

13.9m12.6m19.0m19.9m

Operating expense total

16.0m15.5m23.4m24.1m
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

20.8m185.9m101.6m

Accounts Receivable

3.5m

Prepaid Expenses

479.0k1.2m3.1m

Current Assets

21.2m187.1m243.6m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

44.2m159.8m107.0m133.1m

Accounts Receivable

945.0k2.4m3.7m3.5m

Prepaid Expenses

1.4m2.9m2.9m2.5m

Current Assets

172.8m257.0m225.6m208.6m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(16.9m)(23.8m)(43.3m)

Depreciation and Amortization

434.0k539.0k821.0k

Accounts Payable

285.0k862.0k3.2m

Cash From Operating Activities

(15.4m)7.6m(41.7m)
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(14.6m)(23.5m)(16.7m)(32.6m)

Depreciation and Amortization

365.0k576.0k283.0k569.0k

Accounts Payable

1.2m1.5m(307.0k)(1.1m)

Cash From Operating Activities

(13.9m)(27.6m)(18.9m)(35.3m)
USDFY, 2017

Financial Leverage

1.2 x
Show all financial metrics

Morphic Therapeutic Acquisitions / Subsidiaries

Company NameDateDeal Size
Morphic Security Corporation

Morphic Therapeutic Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Morphic Therapeutic Online and Social Media Presence

Embed Graph

Morphic Therapeutic Company Culture

  • Overall Culture

    A+

    89/100

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    95/100

Learn more on Comparably

Morphic Therapeutic News and Updates

Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conf…

Morphic Therapeutic Announces Appointment of Dr. Martin W. Edwards as Member of its Board of Directors

WALTHAM, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Dr. Martin W. Edwards, to its Board of Directors. Dr. Edwards is a veteran leader in the drug development industry, r…

Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Conference

WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that members of the Morphic management are scheduled to…

Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057

First orally available integrin inhibitor from MInT Platform to enter the clinicMORF-057, inhibitor of α4β7 integrin, in development to treat inflammatory bowel diseasePhase 1 program to assess safety and pharmacokinetics of MORF-057 as well as α4β7 receptor occupancy as a clinically relevant biomar…

Morphic Therapeutic to Present at the Jefferies Next Generation IBD Therapeutics Virtual Summit

WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Next Generation IBD…

Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease at Digestive Disease Week 2020

Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD

Morphic Therapeutic Blogs

Morphic Announces Participation in Upcoming Investor Conferences

Morphic Announces Participation in Upcoming Investor Conferences Content Import Thu, 09/03/2020 - 16:30 Morphic Announces Participation in Upcoming Investor Conferences September 3, 2020 at 4:30 PM EDT This release is a backfill from a News Wire …

Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference

WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief

Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer

WALTHAM, Mass. , April 07, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Marc Schegerin, M.D., as chief financial

Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer

WALTHAM, Mass. , March 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Peter G.

Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference

Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference Content Import Fri, 02/28/2020 - 08:01 Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference February 28, 2020 at 8:00 AM EST This release is a backfill fro…

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019 Content Import Thu, 02/27/2020 - 16:06 Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019 February 27, 2020 at 4:05 PM EST This release is a ba…
Show more

Morphic Therapeutic Frequently Asked Questions

  • When was Morphic Therapeutic founded?

    Morphic Therapeutic was founded in 2015.

  • How many employees does Morphic Therapeutic have?

    Morphic Therapeutic has 76 employees.

  • What is Morphic Therapeutic revenue?

    Latest Morphic Therapeutic annual revenue is $3.4 m.

  • What is Morphic Therapeutic revenue per employee?

    Latest Morphic Therapeutic revenue per employee is $44.2 k.

  • Who are Morphic Therapeutic competitors?

    Competitors of Morphic Therapeutic include MOMA Therapeutics, Zealand Pharma and Twist Bioscience.

  • Where is Morphic Therapeutic headquarters?

    Morphic Therapeutic headquarters is located at 35 Gatehouse Dr, Waltham.

  • Where are Morphic Therapeutic offices?

    Morphic Therapeutic has an office in Waltham.

  • How many offices does Morphic Therapeutic have?

    Morphic Therapeutic has 1 office.